Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1959]

Krdc as induction therapy shows improved OS for NDMM patients

Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK

Krdc as induction therapy shows improved OS for NDMM patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )

Epcoritamab monotherapy is well tolerated and efficacious in patients with R/R...

Dr Alexey Danilov - City of Hope National Medical Center, Los Angeles, USA

Epcoritamab monotherapy is well tolerated and efficacious in patients with R/R CLL ( Dr Alexey Danilov - City of Hope National Medical Center, Los Angeles, USA )

Teclistamab-lenalidomide and teclistamab alone can be safely administered as...

Dr Elena Zamagni - University of Bologna, Bologna, Italy

Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus...

Dr Adam Olszewski - Brown University, Providence, USA

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL ( Dr Adam Olszewski - Brown University, Providence, USA )

Acalabrutinib plus venetoclax with or without obinutuzumab versus...

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA

Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )

Primary IVIG supplementation reduces the risk of high-grade infections in...

Heloise Cheruvalath - Medical College of Wisconsin, Milwaukee, USA

Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy ( Heloise Cheruvalath - Medical College of Wisconsin, Milwaukee, USA )

Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows...

Dr Paolo Caimi - Cleveland Clinic, Cleveland, USA

Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma ( Dr Paolo Caimi - Cleveland Clinic, Cleveland, USA )

Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced...

Dr Peter Abdelmessieh - Fox Chase Cancer Center, Philadelphia, USA

Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem cell mobilisation for MM ( Dr Peter Abdelmessieh - Fox Chase Cancer Center, Philadelphia, USA )

Pembrrolizumab after chemotherapy demonstrates promising activity and...

Prof Christine Mauz-Koerholz - Justus Liebig University, Giessen, Germany

Pembrrolizumab after chemotherapy demonstrates promising activity and manageable safety in patients with low-risk cHL ( Prof Christine Mauz-Koerholz - Justus Liebig University, Giessen, Germany )

Analysis of pre-treatment biomarkers associated with toxicity and durable...

Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA

Analysis of pre-treatment biomarkers associated with toxicity and durable responses in idecabtagene vicleucel therapy for RRMM ( Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA )

Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene...

Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA

Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in RRMM ( Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA )

Bispecific antibody therapy for lymphoma patients failing CAR T-Cell therapy

Dr Matthew Matasar - Rutgers Cancer Institute, New Jersey, USA

Bispecific antibody therapy for lymphoma patients failing CAR T-Cell therapy ( Dr Matthew Matasar - Rutgers Cancer Institute, New Jersey, USA )

More from ecancer